Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 17, 2026

In Vitro Differentiation of Human Mesenchymal Stem Cells into Functional Cardiomyocyte-like Cells
09:05

In Vitro Differentiation of Human Mesenchymal Stem Cells into Functional Cardiomyocyte-like Cells

Published on: August 9, 2017

Human umbilical cord blood mononuclear cells decrease fibrosis and increase cardiac function in cardiomyopathy.

Robert J Henning1, Jeffrey Aufman, Masood Shariff

  • 1Center for Cardiovascular Research, James A Haley Hospital/University of South Florida, 13000 Bruce B. Downs Blvd, 111, Tampa, Florida 33612, FL, USA. robert.henning@va.gov

Regenerative Medicine
|December 19, 2009
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Microbiota-miR-101 interactions in obesity-associated colorectal cancer: from barrier dysfunction to precision therapeutic strategies.

Frontiers in pharmacology·2026
Same author

Novel Pediatric Aggressive Adipose Tumor With Pathogenic TERT Promoter Variant and an Initial Durable Response to Vincristine and Dactinomycin.

Pediatric blood & cancer·2026
Same author

The Progress of Active Immunotherapy for Parkinson's Disease.

International journal of molecular sciences·2026
Same author

Therapeutic antibody delivery: vector tools to boost efficacy and affordability.

Frontiers in immunology·2026
Same author

The critical role of inflammation in atherosclerotic coronary artery heart disease.

Current problems in cardiology·2026
Same author

Corrigendum to "Beneficial effects of a pyrroloquinolinequinone-containing dietary formulation on motor deficiency, cognitive decline and mitochondrial dysfunction in a mouse model of Alzheimer's disease" [Heliyon Volume 3, Issue 4, April 2017, Article e00279].

Heliyon·2025
Same journal

Industry updates in advanced therapy medicinal products and regenerative medicine - May 2026.

Regenerative medicine·2026
Same journal

Ethical, legal, and social issues associated with human fetal tissue research in Japan.

Regenerative medicine·2026
Same journal

The future of hematopoietic stem cell and stem cell gene therapy for metabolic diseases.

Regenerative medicine·2026
Same journal

Exploring gene therapy for developmental and epileptic encephalopathies (DEEs): possibilities or promises?

Regenerative medicine·2026
Same journal

Industry updates in advanced therapy medicinal products and regenerative medicine - April 2026.

Regenerative medicine·2026
Same journal

Optimizing strategies in tendon tissue engineering through effective scaffold design: overview of recent advancements.

Regenerative medicine·2026
See all related articles

Human umbilical cord blood mononuclear cells (HUCBC) show promise in limiting cardiomyopathy progression. This study found HUCBC treatment reduced fibrosis and improved heart function in TO2 hamsters over six months.

Area of Science:

  • Cardiovascular Research
  • Regenerative Medicine
  • Stem Cell Therapy

Background:

  • Progressive cardiomyopathy is a debilitating condition.
  • TO2 hamsters serve as a model for studying inherited cardiomyopathy.
  • Human umbilical cord blood mononuclear cells (HUCBC) are being explored for therapeutic potential.

Purpose of the Study:

  • To investigate the efficacy of HUCBC in limiting progressive cardiomyopathy in TO2 hamsters.
  • To assess the impact of HUCBC on cardiac function and fibrosis.

Main Methods:

  • A total of 22 TO2 hamsters received intramyocardial HUCBC injections, while 23 received Isolyte.
  • Echocardiograms were performed monthly for six months to monitor cardiac function (FS and EF).
  • Heart tissues were analyzed for fibrosis and vascularization using histological staining.

More Related Videos

Neonatal Cardiac Scaffolds: Novel Matrices for Regenerative Studies
08:16

Neonatal Cardiac Scaffolds: Novel Matrices for Regenerative Studies

Published on: November 5, 2016

Related Experiment Videos

Last Updated: Jun 17, 2026

In Vitro Differentiation of Human Mesenchymal Stem Cells into Functional Cardiomyocyte-like Cells
09:05

In Vitro Differentiation of Human Mesenchymal Stem Cells into Functional Cardiomyocyte-like Cells

Published on: August 9, 2017

Neonatal Cardiac Scaffolds: Novel Matrices for Regenerative Studies
08:16

Neonatal Cardiac Scaffolds: Novel Matrices for Regenerative Studies

Published on: November 5, 2016

Main Results:

  • HUCBC treatment significantly slowed the decline in fractional shortening (FS) and ejection fraction (EF) compared to controls.
  • Fibrosis was substantially reduced in the left ventricle and septum of HUCBC-treated hamsters.
  • Increased vascularization was observed in the myocardium of HUCBC-treated hearts.

Conclusions:

  • A single intramyocardial injection of HUCBC can limit fibrosis in TO2 hamsters.
  • HUCBC treatment improves cardiac function in the short term for cardiomyopathy models.
  • HUCBC demonstrates potential as a therapeutic agent for progressive cardiomyopathy.